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The aim of this study was to prospectively evaluate AWBAT-S in comparison with
Biobrane for the treatment of superﬁcial partial-thickness burns using the patient as his
or her own control. Primary outcome measures included length of hospital inpatient stay
and patient-reported perception of pain. Secondary outcome measures included time to
healing, clinical outcome of burn sites (scarring) and a comparison of cost of care for
patients treated with AWBAT-S versus Biobrane.
Superﬁcial partial-thickness burns involve damage to the epidermis and superﬁcial
dermis.1 Thedestroyedtissuetypicallyblistersandsloughsoffleavinganopenandexuding
dermis with nerve endings exposed. They thus represent one of the most painful of the
several categories of thermal injuries. Historically, conservative treatment consisted of
removing nonviable tissue on the ward (the aggressiveness dictated by pain), daily bathing
or showering with friction washing of burn wounds and applying new dressings with
topical medications 1 to 2 times a day.2,3 These procedures cause severe pain and anxiety
in patients, even with the use of opiate analgesics. The management of these injuries at
the Royal Adelaide Hospital (RAH) involves aggressive cleaning under general anaesthetic
immediately, or within 24 hours, after the burn injury and arrival at hospital, followed by
the application of a biosynthetic epithelial replacement (Biobrane, Dow Hickam/Bertek
Pharmaceuticals Inc, Sugarland, Texas; distributed by Smith & Nephew Medical Ltd, Hull,
UK).4 This has been performed with great success in more than 1000 cases over 9 years.5
The application and subsequent ﬁrm adherence of Biobrane, a partly occlusive dress-
ing, allows reepithelialization to occur underneath and eliminates the need for daily
bathing and frequent dressing changes. Although several skin substitutes are available
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commercially, Biobrane (a biosynthetic wound dressing constructed of a silicone ﬁlm with
a nylon fabric partially embedded into the ﬁlm) presents to the wound bed a complex
3-dimensional structure of triﬁlament thread to which collagen has been chemically bound.
Serum exudate clots in the nylon matrix (most likely because of conversion of exudate
ﬁbrinogen to ﬁbrin after exposure to the porcine type 1 collagen peptides), thereby ﬁrmly
adhering the dressing to the wound until epithelialization occurs. It has been effective in
the treatment of partial-thickness burns since 1982.6-18
A more recent product, AWBAT-S (Advanced Wound Bioengineered Alternative
Tissue – Superﬁcial, Aubrey Inc Carlsbad, California), which is comparable in cost to
Biobrane, has been cleared by the US Food and Drug Administration and is commer-
cially available. Although similar in many ways to Biobrane, there are some dissimilarities.
Both materials have a thin medical-grade silicone membrane (0.001-in thick), which con-
trols water vapor transfer and maintains a moist healing environment. Both have a ﬁne
woven nylon fabric (15/3 denier—Biobrane and 15/2 denier—AWBAT), which gives the
skin substitute its strength, elasticity and ability to be surgically secured. Both have pores
inthesiliconemembranetoenableexcessﬂuid/exudatetoescapethewoundsurfacethrough
the skin substitute into a sterile outer dressing. This minimization of ﬂuid accumulation
adjacent to the wound surface reduces proliferation of endogenous wound bacteria. Fluid
accumulation (seroma) also compromises adherence of the skin substitute to the wound
surface, which is the most important property of an effective skin substitute. Biobrane has
pores in the silicone membrane at 1/ 2-in centers. AWBAT-S has pores in the silicone mem-
brane at 1/ 4-in centers. The area of the AWBAT-S pores (8.8 mm2) is larger than the pores in
Biobrane (6.2 mm2) making AWBAT-S approximately 500% more porous than Biobrane.
ThegreaterporosityofAWBAT-Sisexpectedtoresultinimprovedtransferofﬂuid/exudate
from wound surface to outer dressings, which may result in lower rates of infection, better
acute adherence and shorter healing time. Both materials contain collagen peptides for
the purpose of reacting with the ﬁbrin in the wound to achieve good acute adherence. In
Biobrane,cyanuricchloride(acarcinogen)anddodecylamine(anallergen)covalentlybond
the collagen peptide to the silicone-nylon composite. AWBAT-S uses no toxic or allergic
cross-linking agents in its collagen binding. As there is residual dodecylamine in Biobrane,
an allergic reaction mandates removal and prohibits further application. Allergic reactions
are rare with AWBAT-S and allergens have not been demonstrated. Biobrane has low levels
of immobile collagen peptide (porcine type I at approximately 2.5 μg/cm2). AWBAT-S has
more collagen peptides of the same type (at approximately 10 μg/cm2) and highly mo-
bile, which enables the peptides to quickly react with ﬁbrinogen in the wound exudate and
achievetheacuteadherencedesired.Bothmaterialsareprovidedsterileinasealedpackage;
Biobrane is sterilized with an autoclave (live steam) and AWBAT-S by electron beam.
METHODS AND MATERIALS
The study was registered with the Australian New Zealand Clinical Trials Registry and
allocated the registration number ACTRON 12609000765224.
Study population
We intended to enroll all patients admitted with burns expected to heal spontaneously
(who would usually undergo aggressive burn debridement under general anaesthesia and
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Biobrane application). Inpatient treatment over the next 12 months was used for clinical
follow-up visits, scar assessment, clinical outcome assessment, and data analysis.
Study duration
It was anticipated that all subjects would be enrolled and complete their follow-up visits at
12 months post application.
Inclusion/exclusion criteria
For inclusion, patients had to have superﬁcial partial thickness to mid dermal burns with 2
noncontiguous burn sites of the same approximate size/depth for comparison or 1 burn site
large enough to accommodate both a 6-in AWBAT dressing and a 6-in Biobrane dressing.
To enable this, the burn wounds had to range between 2% to 40% total body surface area
(TBSA). The research ethics committee insisted that the patient age ranged from 18 to
70 years. Exclusion criteria included delayed presentation (>48 hours, Biobrane is never
applied after this time in my practice because the burn has “dried out” and cannot be made
to appropriately exude after this time), ventilator dependence, non-English speakers (con-
sent impossible), signs of burn wound infection (another indication for nontreatment with
Biobrane), pregnancy/lactation, burns of unpredictable early depth and course (electrical,
chemicalorfrostbiteinjury)andcomorbiditywhichmaycompromisehealingoranyknown
allergy to porcine products.
Randomization and group allocation
After admission to the Burn Centre, a member of the research team contacted the patient
to invite them to participate in the study. Signed consent (both research and standard
RAH surgical) was obtained following full explanation of the study. The patient was
screened for inclusion/exclusion criteria. The random allocation of dressing locations was
by randomization table and sealed envelopes, which were opened in the operating room
and the wounds dressed in accordance with the instructions provided.
Procedures and Assessments
Once the patient was enrolled and consent obtained, a visual assessment and measurement
of the burn wound(s) was made by the surgeon and recorded. The surgeon matched sites
by approximate size and depth and identiﬁed them anatomically (noncontiguous, right or
left; contiguous, superior or inferior, medial or lateral). Under general anaesthesia, the
burn wounds were meticulously cleaned according to Burn Centre Surgical Protocol which
included shaving any hair from the surface of the burn and for 10 cm around the burn to aid
Hypaﬁx (BSN Medical GmBH, Hamburg, Germany) adhesion and minimize discomfort.
Using the patient-speciﬁc randomization envelope, one burn wound anatomical site
was dressed with AWBAT-S and the other anatomical site was dressed with Biobrane.
Alternatively, both materials were used adjacently on large burns and their respective
positions were randomized. Both AWBAT-S and Biobrane were applied according to the
manufacturer’s instructions (AWBAT-S could only be applied under moderate stretch to
prevent destruction of the 3-dimensional matrix of the skin substitute and compromising
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both acute and secondary adherence). The dressings were secured with sterile Hypaﬁx
tape and covered on the limbs with burns gauze soaked in weak (1 in 10) povidone iodine
solution followed by a crepe bandage (limbs). On the trunk, dressings consisted of Acticoat
(Smith & Nephew Ltd, Hull, UK) and Exudry (Smith & Nephew Ltd, Hull, UK) (posterior)
or Acticoat and Cutilin (DeFries Industries, Melbourne, Australia) (anterior).
The wounds were inspected on day 1 by removing the outer dressings down to the
Biobrane/AWBAT-S layer and assessed for their intactness and complete wound coverage,
seroma or hematoma formation, signs of infection, pain experienced, exudation, quality of
dressing including conformability, pliability, elasticity and any adverse event. Redressing
was performed according to Burns Centre dressing protocols and the dressings used were
recorded on the case report form.
Adult patients were instructed to assess and report pain as 0 to 1, no pain; 2 to 3, mild
pain; 4 to 5, uncomfortable to moderate pain; 6 to 7, distressing to severe pain; 8 to 9,
intense to very severe pain; or 10, unbearable pain. The time of administration, dose, and
route of any analgesia administered within 4 hours of examination was noted on the case
report form.
This process was repeated on day 2 and subsequently as required until healing. After
healing and Biobrane/AWBAT-S separation, a scarring assessment was also made at each
time point using the Vancouver Scale. Digital photographs were taken at every visit after
photographic consent was obtained.
Data analysis
Statistical signiﬁcance was determined by 2-tailed student t-test for parametric data (time
to healing). A 2-tailed t-test was also used to analyze the difference (matched pairs) for
each day between medians for pain scores. A probability level of 0.05 was used as the
criterion for signiﬁcance.
RESULTS
The anticipated recruitment for this study was based on the large number of Biobrane
applications for superﬁcial partial thickness burns over the previous 7 years. However,
disappointingly, a very large number of these injuries presenting within 13 months of the
study commencement met exclusion criteria (speciﬁcally the inability to understand the
study and to provide “informed” consent). After commencement of the study, Aubrey Inc
released what they claim to be a more effective epidermal skin substitute (AWBAT-plus).
These 2 factors together prompted discontinuation of the study after 14 months. The data
produced, however, is important in evaluating the AWBAT platform. The results have been
summarized in Tables 1 and 2.
Length of stay
Generally, the usual length of stay in the Burns Centre at the Royal Adelaide Hospital is
1 day per percent TBSA. This was conﬁrmed during this study (0.88 days per percent
TBSA). This is despite the fact that the specialized nature of Biobrane means that some
patients (rural dwellers—several hours to several days from Adelaide, those whose compli-
ance cannot be relied upon for any reason) are encouraged to stay longer. In this study, only
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in2patients(withthelargestTBSAburns)didthelengthofstayinhospitalexceedthetime
to healing. Both of these patients were referred from areas 4 to 5 hours drive from Adelaide
(Table1).Inonepatient,althoughtheburnwassmaller(6%TBSA),itssite(whichincluded
the groin) caused too much discomfort to allow earlier discharge. In all other cases, the
presence of Biobrane or AWBAT-S did not prove a barrier to discharge. Figure 1 (a − o)
demonstrates a typical progression from admission to healing in AWBAT-S compared to
Biobrane.
Table 1. Length of stay, pain scores, time to healing and total body surface area for all patients
Pain Score Biobrane Pain Score AWBAT Time to Healing
Patient Length Total Body
Number of Stay Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Biobrane AWBAT Surface Area
1 5 6 4 5 4.5 6 3 12 12 2
2 7 7 7 4.5 8 7 4.5 12 12 5
3 1 3001001 1 0 7 3 0
4 4 2 1.5 2 2 1.5 3 10 8 10
5 5 313212 7 7 3
6 5 111111 7 7 7
7 1 0103103 8 8 1 1
8 5 002002 1 3 1 1 8
9 3 320320 8 8 4
1 0 7 013012 1 4 1 4 5
11 7 0 0.5 1 0 0.5 1.5 10 10 2.5
1 2 1 1889889 1 1 1 1 6
Table 2. Median and interquartile range for length of stay, pain scores, and total body surface area
with mean and standard deviation for time to healing
Pain Score Biobrane Pain Score AWBAT Time to Healing
Length of Total Body
stay, Days Day 1 Day 2 Day 3 Day 1 Day 2 Day 3 Biobrane AWBAT Surface Area
Mean 10.17 9.58 7.8
SD 2.33 2.4 7.55
Median 6 1.5 1 2.5 1.5 1 2 5.5
Interquartile
range
2.75 3.75 2.12 2.38 3.38 2.62 1.62 4.75
Time to healing
With small study numbers (n = 12), the mean time to healing between the groups was
not signiﬁcantly different (Biobrane, 10.17 ± 2.33 days compared with AWBAT-S, 9.58 ±
2.39 days, P = .09—Table 2). This might achieve signiﬁcance with larger study groups.
There were some features of healing under AWBAT-S, which made the material different to
Biobrane, such as wrinkling, which gave the appearance of linear nonadherence and caused
concern in a few early patients (Fig 2). This occurred despite the AWBAT-S being applied
ﬂat and under tension. It usually settled by day 5. Once these differences were appreciated,
AWBAT-S was as easy to manage as Biobrane.
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Pain experienced
ThreepatientshadpainscoresthatwereextraordinarilyhighinourexperienceforBiobrane
(No. 1, 2 and 12—Table 1). The individual perception of pain experienced by each patient
canskewdataandthisstudymethodofusingbothmaterialsoneachpatient(bothtreatment
and control arms being subject to individual pain perception) help to negate such outlying
effects. Table1 demonstratesthat the pain scores for both materials in all patientswere very
similar throughout the study. Pain scores up to day 3 have been included, after this point the
pain scores dropped to zero in most patients. There were no signiﬁcant differences between
median pain scores with Biobrane or AWBAT-S at any time point (day 1, P = .49, day 2,
P = .34, day 3, P = .38—Table 2).
Cost of treatment
Subtracting the cost of the material itself (the Australian market cost of AWBAT-
S is not yet known), both materials were identical in terms of outer dressing cost,
nursing attention, and analgesia. Over the 12 patients, 7 days less treatment was re-
quired for wounds dressed with AWBAT-S (although this did not equate to a signiﬁcant
difference).
Figure 1. (a andb)Appearance onpresentation. (c andd)Meticulouscleaninganddebridement.
(e and f) Materials applied (AWBAT-S to forearm, Biobrane to hand). (g) Appearance of both
sites at day 3. (h and i) Both sites healed by day 7. (j and k) Appearance at day 15. (l and m)
Appearance at day 21. (n and o) Appearance at day 28.
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Figure 1. Continued
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Figure 1. Continued
DISCUSSION
I personally believe that the development of Biobrane, with its subsequent widespread
availability, has been an important step in reducing pain and facilitating therapy in burn
injuries expected to heal spontaneously. Those clinicians managing burns who do not use
this material in this indication, favoring more traditional conservative approaches, have
failed to grasp the magnitude of these patient outcomes (in particular pain) and nursing
resource issues (such as a reduction in dressing time). The material is not, however, with-
out its downsides and the meticulousness with which the wound bed must be prepared no
doubt disinclines some surgeons to use it. No less meticulous preparation is needed before
AWBAT-S application. I would suggest, however, that such wound preparation allows an
unparalleled opportunity to decontaminate the wound and fully assess burn depth, degree
of exudation and in some cases (where epidermis is critically injured but not detached)
even burn size. I have also experienced personally the deleterious effect of “delaying in-
tervention to allow the burn to declare.” In refusing to acknowledge the validity of this
claim, and interfering early in the evolving pathophysiological process, I have markedly
reduced my grafting rate with concomitant shortening of length of hospital stay and time
to return to work, reduction in time to full function and improvements in scarring, and
patient satisfaction with cosmetic and functional outcome. My experiences with Biobrane
have been published demonstrating my reliance on it in a range of burn situations.5 When
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Aubrey Woodroof revealed his development of a new, biosynthetic epidermal skin sub-
stitute, AWBAT-S, claiming that he had ironed out some of the problems associated with
Biobrane, I was skeptical and excited at the same time. He claimed that the increased
porosity would decrease the incidence of seroma (which I have never experienced with
Biobrane but which clearly perplexes others) and that the extension of the matrix across the
pores (so that only the silicone layer was deﬁcient at these areas) would reduce the “pore
marks” reported by some authors with Biobrane use. He claimed less “allergic reaction”
(which again I have not experienced with Biobrane). In actual fact, when one considers
my avid loyalty to Biobrane, he was extremely brave to allow me to compare AWBAT-S
against it.
Figure 2. The wrinkling appearance that affected some AWBAT-S in the early stages belies
complete adherence.
Obviously,theoutcomeofthisstudyinsimpletermscouldonlybeoneof2;AWBAT-S
performs better than Biobrane or AWBAT-S does not perform better than Biobrane. In the
case of the former, whether a surgeon changes to a newer material depends also on reliable
availability, ease of access and supply (which can depend heavily on the national local
regulatory body) and cost.
Biobrane’s main advantage over other conservative treatments is its adherence and
elasticity (which prevents shear against the wound bed during dressing changes even with
joint movement, such as metacarpophalangeal joints, proximal interphalangeal joints and
distal interphalangeal joints ﬂexion in making a ﬁst)—these are the properties, which
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reduce pain and speed return to function. There are a number of “surgical” features where,
personally, AWBAT-S is not as good as Biobrane. One such is in its ease of ﬁxation with
ﬁxative tapes. The smoothness of the silicone layer lacks the “texture” of Biobrane and
Hypaﬁx simply does not stick so well to it. Since my application technique for Biobrane
relies heavily on me being able to use tape to stretch and hold the material, this is a major
problem for AWBAT-S.19 In addition, AWBAT-S is nowhere near as elastic as Biobrane and
thus,eachpiececoverslesswoundarea(whichwouldmakeeachtreatmentmorecostly,even
ifbothmaterialscostthesame).ThenewmaterialdoesnotadherelikeBiobrane,remaining
“wrinkled” clinically, which can give the impression that it has not stuck. However, this is
a false impression, which is dispelled during the ﬁrst use.
Figure 3. (a) By day 21, patient number 3 developed prominences at the site of the AWBAT-S
pores. (b) When the redness settled from the healed burn, the pore-marks persisted as raised, pale
scars.
In terms of nursing staff preferences, AWBAT-S is considerably easier and less un-
comfortable to remove than Biobrane. Biobrane has 2 problems in this regard—the ﬁrst
is that the material frequent sticks at the pores due to coagulated exudate, the second is
that Biobrane usually has a “Velcro-like” attachment to the healed burn away from the
pores. The continuation of the nylon matrix across the pores in AWBAT-S removes the ﬁrst
problem. The looser binding of the protein to the matrix in AWBAT-S may be responsible
for the wrinkling appearance and seems to make removal far easier.
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Figure 4. Patient number 10 developed pigmented scars at the pore sites of Biobrane which
persisted at 12 months.
In terms of patients, all preferred AWBAT-S during dressing changes and at removal
to Biobrane.
Aﬁnalissuerelatestoporemarks.Thisisasubjectofcollaborativeinvestigationclose
to publication and I do not want to reveal too much about mechanism here; however, pore
marks were seen in 5 of the 12 patients at the AWBAT-S treatment area compared with
4 of the 12 Biobrane site pore marks. Patient number 2 developed AWBAT-S pore marks
that became prominent between 6 and 12 months and left raised pore scars at 12 months.
Patient number 3, had a particularly unusual AWBAT-S pore-mark reaction, with raised
prominences that persisted, leaving regular and frequent raised white scars (Figs 3a and
3b). In all but one patient (number 10), the Biobrane pore marks faded completely (2 by
3 months, 1 by 6 months); patient number 10 had pore scars from Biobrane at 12 months
(Fig 4). Patient number 12 completely healed a thigh burn in AWBAT-S without any visible
marks, and then developed blisters at the site of the pores after irritation while wearing
nylon track pants (Fig 5). These subsequently healed without scarring. It is obvious that the
pore-mark phenomenon in Biobrane is not a feature of the discontinuity of the nylon matrix
at the pore site, but the discontinuity of the silicone layer. Since AWBAT-S has larger and
more frequent pores, the phenomenon appears to persist for longer, and more frequently
result in pore scars, than when using Biobrane. Finally, the pink colouration of the healed
wound faded more quickly in AWBAT-S–treated areas than Biobrane-treated areas.
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Figure 5. BlisteringatAWBAT-Sporesitesinpatientnumber12followedwearingofnylontrack
pants within a week of healing.
CONCLUSION
AWBAT-S is better than Biobrane in terms of ease of removal and discomfort experienced
by patients at this time. For these reasons, the nursing staff preferred it.
AWBAT-S is at least as good as Biobrane in terms of length of hospital stay, time to
full healing,and pain/discomfort experiencedby patientsduring healing at rest and therapy.
Also, in the general cosmetic appearance of the healed wound under the material proper
(not the pores).
AWBAT-S is not as good as Biobrane at the pore sites where a much greater number
of AWBAT-S sites displayed pore marks compared with Biobrane. It is not as good as
Biobrane in terms of its elasticity or its “‘ﬁx-ability” with adhesive tapes.
Since my practice is about patients, despite my personal happiness with Biobrane,
I would consider a change to AWBAT-S if the pores were made comparable in size and
frequency to Biobrane (ameliorating the pore-mark issue) and if the issues of reliable
availability, regulatory clearance and cost allowed. The material is not so different from
Biobrane that I would accept a higher market cost.
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